Dublin, March 30, 2016 -- Research and Markets has announced the addition of the "Structural Heart Devices Global Market - Forecast to 2022" report to their offering.
The cardiovascular diseases which also include structural heart diseases have become leading cause of death. It is projected that, with newfound prosperity due to globalization and industrialization has led to changing lifestyle increasing risk of younger people developing cardiovascular diseases.
Structural heart devices has emerged as a new focus area of medical device manufacturers as the population of most developed and developing countries continue to become older and risk of cardiovascular diseases increase with aging.
The increased interest has led to development of new technologies and devices that are less invasive and address the need of treatment of patients who are considered too weak to withstand the trauma of an open heart surgery.
The structural heart device market is classified based on type, end-users and geography. The structural heart device market by type is segmented into repair and replacement markets base on the type of procedure performed. The repair segment is further sub segmented into annuloplasty, valvuloplasty and Transcatheter mitral valve repair (TMVR).
The replacement segment is further segmented by technique into surgical valves and Transcatheter aortic valves replacement (TAVR). The surgical valve is sub-segmented as mechanical and tissue heart valves.
The structural heart devices end-user market is segmented into public and private hospitals based on location where the procedures are performed.
Key Topics Covered:
1 Executive Summary
2 Introduction
3 Market Analysis
3.1 Introduction
3.2 Market Segmentation
3.3 Factors Influencing Market
3.3.1 Drivers And Opportunties
3.3.1.1 Prevalence Of Heart Valve Disorders Due To Aging Population
3.3.1.2 Technology Advancements And Growing Healthcare Budgetary Allocation
3.3.1.3 Demand For Minimally Invasive Surgery
3.3.2 Restraints And Threats
3.3.2.1 Strict Regulatory Requirements With High Cost Of Development
3.3.2.2 Lack Of Patient Awareness And Healthcare Infrastructure In Developing Countries
3.3.2.3 High Cost Of Devices And Procedure
3.3.3 Burning Issue
3.3.3.1 Lack Of Trained Professionals
3.4 Regulatory Affairs
3.5 Reimbursement Scenario
3.6 Cpt Codes
3.7 Patent Trends
3.8 Technological Advancements
3.8.1 Tissue Engineering
3.8.2 Polymeric Heart Valves
3.8.3 Sutureless Aortic Valve Replacement (Su-Avr) System
3.8.4 Cardiac Or Ventricular Remodeling
3.8.5 Endoscopic Aortic Valve Replacement (Teavr) System
3.8.6 3-D Printed Model
3.9 Upcoming Technologies
3.10 Clinical Trials
3.11 Porter'S Five Force Analysis
3.11.1 Threat Of New Entrants
3.11.2 Threat Of Substitutes
3.11.3 Bargaining Power Of Suppliers
3.11.4 Bargaining Power Of Buyers
3.11.5 Rivalry Among Existing Competitors
3.12 Market Share Analysis By Major Players
4 Structural Heart Devices Global Market, By Type
4.1 Introduction
4.2 Structural Heart Repair Devices
4.2.1 Annuloplasty
4.2.2 Valvuloplasty
4.2.3 Transcatheter Mitral Valve Repair (Tmvr)
4.3 Structural Heart Replacement Valves
4.3.1 Introduction
4.3.2 Surgical Heart Valve Replacement
4.3.2.1 Mechanical Replacement Heart Valves
4.3.2.2 Biological Replacement Heart Valves (Tissue Valves)
4.3.3 Transcatheter Aortic Valve Replacement(Tavr)
4.3.4 Transcatheter Mitral Valve Replacement (Tmvr)**
5 Structural Heart Devices Global Market, By End-Users
5.1 Introduction
5.2 Public Hospitals
5.3 Private Hospitals
6 Regional Analysis
7 Company Developments
7.1 Introduction
7.2 Approvals
7.3 Mergers & Acquisitions
7.4 New Product Launches
7.5 Agreements & Colloborations
8 Major Companies
8.1 Abbott Laboratories
8.2 Boston Scientific Corpoartion
8.3 Braile Biomedica
8.4 Cryolife, Inc.
8.5 Edwards Lifesciences Corp.
8.6 Jenavalve Technology
8.7 Lepu Medical Technology(Beijing) Co., Ltd.
8.8 Livanova Plc (Sorin Group)
8.9 Medtronic, Plc
8.10 St. Jude Medical, Inc.
Companies Mentioned
- Abbott Laboratories U.S.
- Abiomed Inc. U.S.
- Balton Sp. z o.o. Poland
- Bard Peripheral Vascular, Inc U.S
- BioVentrix, Inc U.S.
- Boston Scientific Corporation U.S.
- Braile bio medica Brazil
- Cardiac Dimensions, Inc. U.S.
- Cardiokinetix Inc U.S.
- Cardiosolutions, Inc U.S.
- Cephea valve technologies U.S.
- Colibri Heart Valve, LLC U.S.
- Coramaze Technologies GmbH Germany
- Cryo life Inc. U.S.
- Direct Flow Medical, Inc U.S.
- Edwards lifesciences Corporation U.S.
- Guided Delivery Systems, Inc. U.S.
- Heart Leaflet Technologies, Inc. U.S.
- HighLife Medical U.S.
- InterValve, Inc U.S
- JenaValve Technology GmbH Germany
- Labcor Laboratórios Ltda. Brazil
- Leman Cardiovascular Switzerland
- Lepu Medical Technology China
- Lifenet Health, Inc. U.S.
- LivaNova PLC UK
- Medtentia International Ltd Oy Finland
- Medtronic PLC Ireland
- MiCardia Corporation U.S.
- Micro Interventional Devices, Inc. U.S.
- MitrAssist Ltd. Israel
- Mitralign, Inc. U.S.
- NaviGate Cardiac Structures Inc. U.S.
- Neovasc Inc Canada
- NuMED, Inc. U.S
- Occlutech Germany
- Osypka AG Germany
- Secant Medical, Inc. U.S.
- St.Jude Medical Corporation U.S.
- Symetis SA Switzerland
- TTKChitra HeartValve India
- The Phoenix Cardiac device Pvt. Ltd. India
- Thubrikar Aortic Valve, Inc. U.S.
- TransCardiac Therapeutics, LLC U.S.
- Transcatheter Technologies GmbH Germany
- Valcare Medical, Inc. Israel
- Valtech Cardio, Ltd Israel
- Venus Medtech (Hangzhou) Inc. China
- W. L. Gore and Associates, Inc. U.S.
- Xuzhou Yatai Scientific CO.,LTD
For more information visit http://www.researchandmarkets.com/research/rtr6j6/structural_heart
CONTACT: Research and Markets
Laura Wood, Senior Manager
[email protected]
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: Cardiovascular Devices


Saks Global Weighs Chapter 11 Bankruptcy Amid Debt Pressures and Luxury Retail Slowdown
Dina Powell McCormick Resigns From Meta Board After Eight Months, May Take Advisory Role
Uber and Baidu Partner to Test Robotaxis in the UK, Marking a New Milestone for Autonomous Ride-Hailing
FDA Fast-Tracks Approval of Altria’s on! PLUS Nicotine Pouches Under New Pilot Program
U.S. Lawmakers Urge Pentagon to Blacklist More Chinese Tech Firms Over Military Ties
Novo Nordisk Stock Surges After FDA Approves Wegovy Pill for Weight Loss
Mexico Antitrust Review of Viva Aerobus–Volaris Deal Signals Growth for Airline Sector
FedEx Beats Q2 Earnings Expectations, Raises Full-Year Outlook Despite Stock Dip
FTC Praises Instacart for Ending AI Pricing Tests After $60M Settlement
Moore Threads Unveils New GPUs, Fuels Optimism Around China’s AI Chip Ambitions
JPMorgan’s Top Large-Cap Pharma Stocks to Watch in 2026
7-Eleven CEO Joe DePinto to Retire After Two Decades at the Helm
Google and Apple Warn U.S. Visa Holders to Avoid International Travel Amid Lengthy Embassy Delays
Maersk Vessel Successfully Transits Red Sea After Nearly Two Years Amid Ongoing Security Concerns
Elon Musk Wins Reinstatement of Historic Tesla Pay Package After Delaware Supreme Court Ruling
Italy Fines Apple €98.6 Million Over App Store Dominance
Boeing Seeks FAA Emissions Waiver to Continue 777F Freighter Sales Amid Strong Cargo Demand 



